Geron Corporation (GERN) Says FDA Halts Patient Enrollment In Another Cancer Trial
3/20/2014 7:29:54 AM
Geron Corp said the U.S. Food and Drug Administration ordered a halt to new patient enrollments in an early-stage trial of its blood cancer drug, imetelstat, over concerns about liver damage. The halt announced on Thursday was for enrollments in a trial sponsored by Mayo Clinic, and comes a week after the FDA ordered Geron to cease company-sponsored trials of the drug over similar concerns. Imetelstat is Geron's only remaining drug and was touted as the company's savior after curing 22 percent of myelofibrosis patients in a trial last year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by